|
3 Companies |
|
4 Products |
|
4 Products |
|
3 Mechanisms of Action |
|
0 Trials |
|
13 News |
|
- | NN1213 / Novo Nordisk
Trial completion: Clinical and Genetic Studies of Familial Presenile Dementia With Neuronal Inclusion Bodies (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=100, Completed, Sponsor: National Human Genome Research Institute (NHGRI)
Suspended --> Completed
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Trial completion, Phase classification, Trial primary completion date: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Feb 17, 2017
P2, N=36, Completed, Sponsor: Horizon Orphan LLC
Suspended --> Completed Enrolling by invitation --> Completed | Phase classification: P2/3 --> P2 | Trial primary completion date: Mar 2016 --> Oct 2016
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Enrollment status: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Jan 30, 2016
P2/3, N=32, Enrolling by invitation, Sponsor: Raptor Pharmaceuticals Inc.
Enrolling by invitation --> Completed | Phase classification: P2/3 --> P2 | Trial primary completion date: Mar 2016 --> Oct 2016 Recruiting --> Enrolling by invitation
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Trial primary completion date: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Apr 25, 2015
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Recruiting --> Enrolling by invitation Trial primary completion date: Dec 2015 --> Mar 2016
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Trial primary completion date: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Feb 23, 2015
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Aug 2015 --> Dec 2015
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Trial primary completion date: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Oct 2, 2014
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Jan 2015 --> Jun 2015
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Trial initiation date: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Apr 15, 2014
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Trial primary completion date: Jan 2015 --> Jun 2015 Initiation date: Mar 2014 --> Apr 2014
- | Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
Enrollment open: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Mar 24, 2014
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- ||| Procysbi (cysteamine bitartrate delayed release) / Chiesi, Amgen
New P2/3 trial: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (clinicaltrials.gov) - Dec 26, 2013
P2/3, N=32, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
- | lacosamide / Generic mfg.
Trial completion: Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy (clinicaltrials.gov) - Oct 25, 2012
P2, N=39, Completed, Sponsor: UCB, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | lacosamide / Generic mfg.
Trial completion: Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy (clinicaltrials.gov) - Sep 7, 2011
P2, N=49, Completed, Sponsor: UCB, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed